Skip to main content
SpringerLink
Log in

Effete immunologiques et anti-inflammatoires des médicaments utilisés dans le traitement des maladies inflammatoires idiopathiques de ľintestin

Immunological and anti-inflammatory actions of drugs used in the treatment of inflammatory bowel disease

Efectos inmunológicos y anti-inflamatorios de medicamentos utilizados en el tratamiento de enfermedades inflamatorias idiopáticas intestinales

  • Published:
Acta Endoscopica

Résumé

Alors que certains mécanismes pathogéniques responsables des maladies inflammatoires idiopathiques de ľintestin commencent à être connus, notamment le rôle de certains médiateurs inflammatoires et immunologiques comme le leucotriène B4 et ľinterleukine-2, les modes ďaction des divers médicaments démontrés efficaces ďaprés des études contrôlées commencent aussi à être élucidés comme il est précisé dans cette revue. Mais plusieurs de ces médicaments, comme la sulfasalazine et ses dérivés, ont des mécanismes ďaction potentiels multiples, anti-inflammatoires et immunologiques. II est dès lors difficile ďattribuer ľefficacité ďun médicament à telle ou telle action spécifique. Les dernières études, évaluant à la fois ľefficacité ďun médicament et son action sur un médiateur inflammatoire ou immunologique, paraissent prometteuses.

Summary

At a time when certain pathogenic mechanisms of inflammatory bowel disease are beginning to be identified, for example the intervention of certain inflammatory or immunological mediators, such as leucotriene B4 and interleukin-2, several anti-inflammatory and/or immunological effects of drugs demonstrated efficient in IBD by controlled trials are also being discovered as outlined in this review. However, the specific therapeutic benefit of these effects is not yet known. Recent studies aimed at evaluating both the therapeutic effect of a drug and its action(s) on an inflammatory or immunological mediator are promising.

Resumen

Al tiempo que ciertos mecanismos patogénicos de la enfermedad inflamatoria intestinal comienzan a identificarse, por ejemplo la intervención de ciertos mediadores inflamatorios o inmunológicos como el leucotrieno B4 y la interleukina-2, varios efectos antiinflamatorios y/o inmunológicos de medicamentos demostrados eficientes en estudios controlados, comienzan tambien a ser dilucidados como se describe en esta revisión. Sinembargo la terapéutica benéfica específica de estos efectos aún es desconocida. Los últimos estudios evaluando a la vez la eficacia de un medicamento y su acción sobre un mediador inflamatorio o inmunológico, parecen prometedores.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Références

  1. BRANDTZAEG P., HALSTENSEN T.S., HELGELAND L., KETT K. — The mucosal system in inflammatory bowel disease.Acta endoscopica, 1990, 20, 203 (abstract).

    Google Scholar 

  2. CUVELIER C. — Lymphoepithelial interactions in normal and IBD mucosa: morphological aspects of antigen presentation.Acta endoscopica, 1990, 20, 204(abstract).

    Google Scholar 

  3. JEWELL D.P. — Cytokines and the intestinal immune response.Acta endoscopica, 1990, 20, 205 (abstract).

    Google Scholar 

  4. LIGUMSKY M., SIMON P.L., KARMELI F., RACHMILEWITZ D. — Role of interleukin 1 in inflammatory bowel disease — enhanced production during active disease.Gut, 1990, 31, 686–689.

    Article  PubMed  CAS  Google Scholar 

  5. BRYNSKOV J., TUEDE N. — Plasma interleukin-2 and a soluble/shed interleukine-2 receptor in serum of patients with Crohn’s disease. Effect of cyclosporine.Gut, 1990, 31, 795–799.

    Article  PubMed  CAS  Google Scholar 

  6. MUELLER Ch., KNOFLACH P., ZIELINSKJ C.C. — T-cell activation in Crohn’s disease. Increase levels of soluble interleukine-2 receptor in serum and in supernatants of stimulated peripheral blood mononuclear cells.Gastroenterology, 1990, 98, 639–646.

    PubMed  CAS  Google Scholar 

  7. CRABTREE J.E., JUBY L.D., HEALLEY R.V., LOBO A.J., BULLIMORE D.W., AXON A.T.R. — Soluble interleukin-2 receptor in Crohn’s disease: relation of serum concentrations to disease activity.Gut, 1990, 31, 1033–1036.

    Article  PubMed  CAS  Google Scholar 

  8. BRANDTZAEG P., HALSTENSEN T.S., KETT K., KRAJCI P., KVALE D., ROGNUM T.O., SCOTT H., SOLLID L.M. — Immunobiology and immunopathology of human gut mucosa: humoral immunity and intraepithelial lymphocytes.Gastroenterology, 1989, 97, 1562–1584.

    PubMed  CAS  Google Scholar 

  9. RACHMILEWITZ D., KARMELI F., ELIAKIM R. — Platelet-activating factor — a possible mediator in the pathogenesis of ulcerative colitis.Scand. J. Gastroenterol., 1990, 25 (suppl. 172), 19–21.

    Article  Google Scholar 

  10. DAS K.M. — Sulfasalazine therapy in inflammatory bowel disease.Gastroenterol. Clin. North. Am., 1989, 18, 1–20.

    PubMed  CAS  Google Scholar 

  11. AZAD KAHN A.K., PIRIS J., TRUELOVE S.C. — An experiment to determine the active therapeutic moiety of sulphasalazine.Lancet, 1977, ii: 892–895.

    Article  Google Scholar 

  12. IRELAND A., JEWELL D.P. — Sulphasalazine and the new salicylates.Europ J Gastroenterol Hepatol, 1989, 1, 43–50.

    Google Scholar 

  13. BASILISCO G., RANZI T., CAMPANINI M. et al. — 5-aminosalicylic acid or sulfasalazine retention enemas in distal ulcerative colitis. A randomized therapeutic trial.Curr Ther Res, 1987, 42: 910–915.

    Google Scholar 

  14. CAMPIERI M., GIONCHETTI P., BELLUZZI A. et al. — Efficacy of 5- aminosalicylic acid enemas versus hydrocortisone enemas in ulcerative colitis.Dig Dis Sci, 1987, 32: 67S-70S.

    Article  PubMed  CAS  Google Scholar 

  15. MULDER C.J.J., TYTGAT G.N.J., WILTINK E.H.H., HOUTHOFF H.J. — Comparison of 5-aminosalicylic acid (3 g) and prednisolone phosphate sodium enemas (30 mg) in the treatment of distal ulcerative colitis. A prospective randomized, double-blind trial.Scand. J. Gastroenterol., 1988, 23: 1005–1008.

    Article  PubMed  CAS  Google Scholar 

  16. MAHIDA Y.R., JEWELL D.P. — Slow-release 5-aminosalicylic acid (PentasaR) for the treatment of active Crohn’s disease.Digestion, 1990, 45, 88–92.

    PubMed  CAS  Google Scholar 

  17. HANAUER S.B., BELKER M.E., GITNICK G., KRAWITT E., ROUFAIL W., WRUBLE L., WILKINSON C.M. — Multi-center, placebo-controlled dose- ranging study of oral pentasa (controlled-release mesalamine) for active Crohn’s disease: preliminary results.Gastroenterology, 1990, 98, A173 (Abstract).

    Google Scholar 

  18. INTERNATIONAL MESALAZINE STUDY GROUP. — Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn’s disease.Aliment. Pharmacol. Ther., 1990, 4, 55–64.

    Google Scholar 

  19. GENDRE J.P., MARY J.Y., FLORENT C. et al. — Does pentasa prevent relapses in quiescent Crohn’s disease? A multicenter placebo-controlled trial.Gastroenterology, 1990, 98, A171 (Abstract).

    Google Scholar 

  20. PULLAR T., HUNTER J.A., CAPELL H.A. — Sulphasalazine in rheumatoid arthritis: a double-blind comparison of sulphasalazine with placebo and sodium aurothiomalate.Br. Med. J., 1983, 287, 1102–1104.

    Article  CAS  Google Scholar 

  21. PINALS RS, KAPLAN S.B., LAWSON JG et al. — Sulfasalazine in rheumatoid arthritis. A double-blind, placebo - controlled trial.Arthritis Rheum, 1986, 29, 1427–1434.

    Article  PubMed  CAS  Google Scholar 

  22. PULLAR T., HUNTER S.A., CAPELL H.A. — Which component of sulphasalazine is active in rheumatoid arthritis?Br. Med. J., 1985, 290, 1535–1538.

    CAS  Google Scholar 

  23. NEUMANN V.C., TAGGART A.J., LE GALLEZ P., ASTBURY C., HILL J., BIRD H.A. — A study to determine the active moiety of sulphasalazine in rheumtaoid arthritis.J. Rheumatol., 1986, 13, 285–287.

    PubMed  CAS  Google Scholar 

  24. IRELAND A., JEWELL D.P. — Mechanism of action of 5-aminosalicylic acid and its derivatives.Clin. Sci., 1990, 78, 119–115.

    PubMed  CAS  Google Scholar 

  25. PESKAR B.M., DREYLING K.W., MAY B., SCHAARSCHMIDT K., GOEBELL H. — Possible mode of action of 5-aminosalicylic acid.Dig. Dis. Sci., 1987, 32 suppl., 51S-56S.

    Article  PubMed  CAS  Google Scholar 

  26. LAURITSEN K., LAURSEN L.S., BUKHAVE K., RASK-MADEN J. — Effects of topical 5-aminosalicylic acid and prednisolone on prostaglandin E2 and leukotriene B4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis.Gastroenterology, 1986, 91, 837–844.

    PubMed  CAS  Google Scholar 

  27. SHARON P., STENSON W.F. — Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease.Gastroenterology, 1984, 86, 453–460.

    PubMed  CAS  Google Scholar 

  28. RASK-MADSEN J., BUKHAVE K., LAURITSEN K. — Functional role of eicosanoids in the gastrointestinal tract.Acta gastroenterol. belg., 1988, 51, 439–449.

    PubMed  CAS  Google Scholar 

  29. RAMPTON D.S., SLADEN G.E. — Relapse of ulcerative proctocolitis during treatment with non-steroidal anti-inflammatory drugs.Postgrad. Med. J., 1981, 57, 297–299.

    PubMed  CAS  Google Scholar 

  30. SIRCAR J.C., SCHWENDER C.F., CARETHERS M.E. — Inhibition of soybean lipoxygenase by sulfasalazine and 5-aminosalicylic acid: a possible mode of action in ulcerative colitis.Biochem. Pharmacol, 1983, 32, 170–171.

    Article  PubMed  CAS  Google Scholar 

  31. STENSON W.F., MEHTA J., SPILBERG — 1 Sulphasalazine inhibition of N-formyl-methionyl-leucyl-phenilalanine (FMLP) to its receptor on human neutrophils.Biochem. Pharmacol., 1984, 33, 407–412.

    Article  PubMed  CAS  Google Scholar 

  32. NEAL T.M., WINTERBOURN C.C., VISSERS M.C.M. — Inhibition of neutrophil degranulation and superoxide production by sulfasalazine. Comparison with 5-aminosalicylic acid, sulfapyridine and olsalazine.Biochem. Pharmacol., 1987, 36, 2765–2768.

    Article  PubMed  CAS  Google Scholar 

  33. HILLEX K.O., WILLSON R.L. — Hydroxyl free radicals and anti-inflammatory drugs: biological inactivation studies and reaction rate constants.Biochem. Pharmacol., 1983, 13, 2109–2111.

    Google Scholar 

  34. MACDERMOTT R.P., SCHLOEMANN S.R., BERTOVICH M.J., NASH G.S., PETERS M., STENSON W.F. — Inhibition of antibody secretion by 5- aminosalicylic acid.Gastroenterology, 1989, 96, 442–448.

    PubMed  CAS  Google Scholar 

  35. APARICIO-PAGES M.N., VERSPAGET H.W., HACKENSCHEID J.C.M., CRAMA-BOHBOUTH G.E., PENA A.S., WETERMAN I.T., LAMERS C.B.M.W. — Inhibition of cell mediated cytotoxicity by sulphasalazine: effect of in vivo treatment with 5-aminosalicylic acid and sulphasalazine on in vitro natural killer cell activity.Gut, 1990, 31, 1030–1032.

    Article  PubMed  CAS  Google Scholar 

  36. JEWELL D.P. — Corticosteroids for the management of ulcerative colitis and Crohn’s disease.Gastroenterol. Clin. North Am., 1989, 18, 21–34.

    PubMed  CAS  Google Scholar 

  37. MALCHOW H., EWE K., BRANDES J.W., GOEBELL H., EHMS H., SOMMER H., JESPINSKY H. — European cooperative Crohn’s disease study: results of drug treatment.Gastroenterology, 1984, 86, 249–266.

    PubMed  CAS  Google Scholar 

  38. DREWS J. —Immunopharmacology. Principles and perspectives. Editions « Roche º, Basel, 1990.

  39. HARRISON R.W., LIPPMAN S. — How steroid hormones work.Hosp. Pract., 1989, 24, 63–76.

    Google Scholar 

  40. GOULDING N.J., GODOLPHN J.L., SHARLAND P.P., PEERS S.H., SAMPSON M., MADDISON P.J., FLOWER R.J. — Anti-inflammatory lipocortin 1 production by peripheral blood leucocytes in response to hydrocortisone.Lancet, 1990, 335, 1416–1418.

    Article  PubMed  CAS  Google Scholar 

  41. ROUTES J., CLAMAN H.N. — Corticosteroids in inflammatory bowel disease. A review.J. Clin. Gastroenterol., 1987, 9, 529–535.

    Article  PubMed  CAS  Google Scholar 

  42. HAWTHORNE A.B., HAWKEY C.J. — Immunosuppressive drugs in inflammatory bowel disease. A review of their mechanisms of efficacy and place in therapy.Drugs, 1989, 38, 267–288.

    PubMed  CAS  Google Scholar 

  43. GOLDSTEIN F. — Immunosuppressant therapy of inflammatory bowel disease. Pharmacologic and clinical aspects.J. Clin. Gastroenterol., 1987, 9, 654–658.

    Article  PubMed  CAS  Google Scholar 

  44. KLEIN M., BINDERH J., MITCHELL M., AARONSON R., SPIRO M. — Treatment of Crohn’s disease with azathioprine: a controlled evaluation.Gastroenterology, 1987, 66, 916–922.

    Google Scholar 

  45. PRESENT D.H., KORELITZ B.I., WISCH N., SACHAR D.B., PASTERNACK B.S. — Treatment of Crohn’s disease with б-mercaptopurine. A long-term, randomized, double-blind study.N. Engl. J. Med., 1980, 302, 981–987.

    PubMed  CAS  Google Scholar 

  46. PRESENT D.H., CHAPMAN M.L., RUBIN P.H. — Efficacy of б-mercaptopurine in refractory ulcerative colitis.Gastroenterology, 94: A359, 1988.

    Google Scholar 

  47. CAMPBELL A.C., SKINNER J.M., HERSEY P., et al. — Immunosuppression in the treatment of inflammatory bowel disease. 1. Changes in lymphoid subpopulations in the blood and rectal mucosa following cessation of treatment with azathioprine.Clin. Exp. Immunol., 1974, 16, 521–533.

    Google Scholar 

  48. CAMPBELL A.C., SKINNER R.J.M., MACLENNAN I.C.M., HERSEYP., WALLER C.A. — Immunosuppression in the treatment of inflammatory bowel disease. II. The effect of azathioprine on lymphoid cell population in a double blind trial in ulcerative colitis.Clin. Exp. Immunol., 1976, 24, 249–258.

    PubMed  CAS  Google Scholar 

  49. DANIELSON D. — Antibacterial activity of azathioprine (Imuran ®) against anaerobic intestinal bacteria - implications in Crohn’s disease. In BROOKE B.N., WILKINSON A.W. (ed.).Inflammatory Disease of the Bowel, Pitman Medical, Tunbridge Wells, Kent, 1980, pp 187–188.

  50. BRYNSKOV J., FREUND L., NORBY RASMUSSEN S., et al. — A placebo- controlled double-blind, randomized trial of cyclosporine therapy in active Crohn’s disesae.N. Engl. J. Med., 1989, 321, 845–850.

    PubMed  CAS  Google Scholar 

  51. LICHTIGER S., PRESENT D.H. — Preliminary report: cyclosporin in treatment of severe active ulcerative colitis.Lancet, 1990, 336, 16–19.

    Article  PubMed  CAS  Google Scholar 

  52. VAN THIEL D.H. — Cyclosporine and inflammatory bowel disease.Dig. Dis. Sci., 1989, 34, 1817–1818.

    Article  PubMed  Google Scholar 

  53. KAHAN B.D. — Cyclosporine.N. Engl. J. Med., 1989, 321, 1725–1738.

    PubMed  CAS  Google Scholar 

  54. URSING B., ALM T., BARANY F. et al. — A cooperative study of metronidazole and sulfasalazine for active Crohn’s disease. The cooperative Crohn’s disease study in Sweden. II. Result.Gastroenrerology, 1982, 83, 550- 562.

    CAS  Google Scholar 

  55. KOZAREK R.A., PATIERSON S.J., BOTOMAN V.A., BALL T.J., GELFAND M.D. — Methotrexate, the long and the short of it.Gastroenterology, 1990, 98, A183.

    Google Scholar 

  56. LAURSEN L.S., NAESDAL J., BUKHAVE K., LAURITSEN K., RASK-MADSEN J. — Selective 5-lipoxygenase inhibition in patients with ulcerative colitis: effects of ABBOTF-64077.Gastroenlerology, 1990, 98, A185.

    Google Scholar 

  57. TOBIN A., SUZUKI Y., O’MORAIN C. — Controlled double blind cross over study of eicosapentanoic acid in chronic ulcerative colitis.Gastroenlerology, 1990, 98, A207.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service de Gastro-entérologie, Université Catholique de Louvain, Bruxelles (Belgique)

    R. Fiasse

Authors
  1. R. Fiasse
    View author publications

    You can also search for this author in PubMed Google Scholar

About this article

Cite this article

Fiasse, R. Effete immunologiques et anti-inflammatoires des médicaments utilisés dans le traitement des maladies inflammatoires idiopathiques de ľintestin. Acta Endosc 21, 261–274 (1991). https://doi.org/10.1007/BF02968715

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02968715

Mots-clés

Key-words

Palabras claves

Search

Navigation